A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Vision Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. Our Company We are a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Our partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we develop. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 2.8M | - | - | - |
| Net Income | -75M | -61M | -49M | -34M |
| EPS | $-1.80 | $-1.66 | $-1.48 | $-2.24 |
| Free Cash Flow | -61M | -51M | -46M | -30M |
| ROIC | -661.4% | -66.7% | -72.2% | -54.2% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.43 | 0.40 | 0.18 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -75M | -64M | -52M | -33M |
| Operating Margin | -2669.9% | - | - | - |
| ROE | -71.7% | -95.2% | -72.2% | -64.0% |
| Shares Outstanding | 56M | 37M | 33M | 15M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 2.8M |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -33M | -52M | -64M | -75M |
| Op. Margin | N/A | N/A | N/A | -2669.9% |
| Net Income | -34M | -49M | -61M | -75M |
| Net Margin | N/A | N/A | N/A | -2665.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -54.2% | -72.2% | -66.7% | N/M |
| ROE | -64.0% | -72.2% | -95.2% | -71.7% |
| ROA | -35.2% | -51.6% | -71.2% | -5794.8% |
| Cash Flow | ||||
| Op. Cash Flow | -29M | -46M | -51M | -60M |
| Free Cash Flow | -30M | -46M | -51M | -61M |
| Owner Earnings | -33M | -54M | -61M | -71M |
| CapEx | 591K | 78K | 289K | 562K |
| Maint. CapEx | 222K | 287K | 308K | 308K |
| Growth CapEx | 369K | 0 | 0 | 254K |
| D&A | 222K | 287K | 308K | 308K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.4M | 7.6M | 11M | 11M |
| Debt Repayment | 6.4M | 11M | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -74M | N/A | -53M | -96M |
| Cash & Equiv. | N/A | N/A | N/A | 96M |
| Long-Term Debt | 9.5M | N/A | 14M | 14M |
| Debt/Equity | 0.18 | 0.40 | 0.43 | 0.00 |
| Interest Coverage | -47.9 | -13.4 | -19.2 | -19.2 |
| Equity | 53M | 68M | 33M | 105M |
| Total Assets | 96M | 95M | 76M | 1.3M |
| Total Liabilities | 43M | 27M | 43M | 61M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -200M | -249M | -310M | -310M |
| Working Capital | 66M | 78M | 53M | 53M |
| Current Assets | 85M | 89M | 69M | 69M |
| Current Liabilities | 19M | 11M | 16M | 16M |
| Per Share Data | ||||
| EPS | -2.24 | -1.48 | -1.66 | -1.80 |
| Owner EPS | -2.19 | -1.63 | -1.67 | -1.26 |
| Book Value | 3.50 | 2.05 | 0.90 | 1.86 |
| Cash Flow/Share | -1.95 | -1.39 | -1.38 | -1.32 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 15.0M | 33.2M | 36.8M | 56.5M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -2.5 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 2.8 | 4.7 | 4.9 | 2.4 |
| Price/Sales | N/A | N/A | N/A | 90.4 |
| FCF Yield | -20.0% | -14.4% | -31.4% | -23.9% |
| Market Cap | 149M | 320M | 162M | 255M |
| Avg. Price | 9.92 | 10.05 | 6.14 | 4.51 |
| Year-End Price | 9.94 | 9.64 | 4.40 | 4.51 |
Orchestra BioMed Holdings, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Orchestra BioMed Holdings, Inc. (OBIO) has a 5-year average return on invested capital (ROIC) of -64.4%. This is below average and may indicate limited pricing power.
Orchestra BioMed Holdings, Inc. (OBIO) has a market capitalization of $255M. It is classified as a small-cap stock.
Orchestra BioMed Holdings, Inc. (OBIO) does not currently pay a regular dividend.
Orchestra BioMed Holdings, Inc. (OBIO) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Orchestra BioMed Holdings, Inc. (OBIO) generated $-51 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Orchestra BioMed Holdings, Inc. (OBIO) has a debt-to-equity ratio of 0.43. This indicates a conservatively financed balance sheet.
Orchestra BioMed Holdings, Inc. (OBIO) reported earnings per share (EPS) of $-1.66 in its most recent fiscal year.
Orchestra BioMed Holdings, Inc. (OBIO) has a return on equity (ROE) of -95.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Orchestra BioMed Holdings, Inc. (OBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Orchestra BioMed Holdings, Inc. (OBIO) has a book value per share of $0.90, based on its most recent annual SEC filing.